- AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the SERENA-2 Phase 2 trial of camizestrant in pretreated post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.
- The data showed that camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at 75mg and 150mg dose levels versus Faslodex (fulvestrant) 500mg in patients previously treated with endocrine therapy.
- In the overall population, camizestrant significantly reduced the risk of disease progression or death by 42% at a 75mg dose with a median PFS of 7.2 versus 3.7 months and 33% at a 150mg dose with median PFS of 7.7 versus 3.7 months compared to Faslodex, the current SERD standard of care.
- Among the prespecified subgroup of patients with ESR1 mutations, camizestrant showed a 67% reduction in the risk of disease progression or death at a 75mg dose and a 45% reduction at a 150mg dose.
- The company also announced detailed results from the CAPItello-291 Phase 3 trial of capivasertib + Faslodex (fulvestrant) combo in patients with hormone receptor (HR)-positive, HER2-low or negative, locally advanced or metastatic breast cancer.
- Results showed capivasertib in combination with Faslodex demonstrated a 40% reduction in the risk of disease progression or death versus placebo plus Faslodex in the overall trial population.
- Price Action: AZN shares are up 0.75% at $69.36 on the last check Thursday.
- Photo Via Wikimedia Commons
Walmart Unveils Plans For Futuristic Fulfillment Hub In Stockton, California
Walmart Inc. (NYSE: WMT) plans to open its fifth 'next-generation'
